The Association Between Vascular Inflammation and Depressive Disorder. Causality, Biomarkers and Targeted Treatment

Area of Science:

• Integrative medicine and neuroscience, focusing on the interplay between cardiovascular health and mental well-being.

Background:

• Major depressive disorder frequently co-occurs with cardiovascular and metabolic diseases like diabetes, obesity, and atherosclerosis.
• Existing research suggests a potential common link between these conditions, necessitating a deeper investigation into shared underlying mechanisms.

Purpose of the Study:

• To review the evidence supporting vascular inflammation as a common pathophysiological factor in major depressive disorder and comorbid conditions.
• To explore the role of endothelial dysfunction in the blood-brain barrier as a potential mediator for depression symptoms.
• To identify biomarkers of vascular inflammation and discuss potential therapeutic strategies targeting this pathway for depression.

Main Methods:

• Review of existing literature on the co-morbidity of major depressive disorder with vascular and metabolic diseases.
• Analysis of proposed biomarkers for vascular inflammation, including C-reactive protein, cell-adhesion molecules, and inflammatory cytokines.
• Examination of potential therapeutic interventions targeting vascular inflammation, such as eicosapentaenoic acid (EPA) and vagus nerve stimulation.

Main Results:

• Vascular inflammation is proposed as a unifying factor in major depressive disorder and conditions such as diabetes, obesity, and atherosclerosis.
• Endothelial dysfunction of the blood-brain barrier may contribute to the development of depressive symptoms.
• Biomarkers including elevated C-reactive protein, soluble cell-adhesion molecules, and specific cytokines indicate vascular inflammation.

Conclusions:

• Treating vascular inflammation holds promise for preventing or alleviating symptoms of depression.
• Potential therapeutic avenues include eicosapentaenoic acid (EPA), valproate, vagus nerve stimulation, and specific receptor agonists.
• Further research is warranted to validate these findings and optimize treatment strategies for inflammation-related depression.